All three tenses have at least two readings, so the archetype blend applies as printed.
All nine metrics read as filed from the record.
What did they actually do?
Has it survived what it has been through?
2 warning events since 2017; the latest 2017-05-05.
From the record
Anika Therapeutics Inc.'s filings since 2017 show 2 warning events: an auditor change (8-K item 4.01, 2 times, the latest 2017-05-05) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+1% a year over 10 filed years; profitable in 5 of 10.
From the record
Anika Therapeutics Inc.'s 10 filed years say what it did: revenue went from $103 million in fiscal 2016 to $113 million in fiscal 2025, up 1% a year; it rose in 5 of 9 years; the deepest fall was 24% from fiscal 2021 to fiscal 2025; net income was positive in 5 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
Share count shrank 1.0% a year. 100% of cash flow returned. Insiders: 0 sales, 4 purchases.
From the record
Over the 3 fiscal years to 2025-12-31, Anika Therapeutics Inc.'s diluted share count shrank about 1.0% a year, and dividends and buybacks returned about 100% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 0 sales and 4 purchases of their own stock on the open market in the year to 2026-09-30, buying about $264 thousand (their Form 4 filings).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they doing right now?
Is it financially healthy right now?
ROE -8%: lost 8¢ per shareholder dollar. Leverage 25%: owes 25¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Anika Therapeutics Inc. lost about 8 cents for every dollar of shareholders' money, and gross profitability: its products earned about 34 cents per dollar of everything the company owns. Leverage: it owed about 25 cents per dollar of assets, and net share issuance: its share count shrank 2.6% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 46% of 109 in its family; net margin -9.6%.
From the record
Anika Therapeutics Inc.'s standing among 109 graded names in its industry family: revenue of $113 million in fiscal 2025 ranks in the top 44% by size; a net margin of -9.6% ranks in the top 39%; revenue growth of -0.3% a year over the last 3 filed years ranks in the bottom 23% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 26% of 91 in its family for leadership; chief executive since 2026.
From the record
Anika Therapeutics Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Griffin, Stephen D. (President and CEO, as filed), filing under that title since 2026-02-03, 9 months (bottom 16% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 5 years (bottom 43%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (bottom 19%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 39% of 104 in its family for room to expand.
From the record
Anika Therapeutics Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $57 million against no long-term debt tagged leaves 30.2% of its assets as net cash, top 29% of its family; cash from operations less capital spending is 3.9% of revenue (top 33%); a gross margin of 56.6% (bottom 43%); research spending of 22.8% of revenue (top 36%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 44% of 105 in its family for growth drivers.
From the record
Anika Therapeutics Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -0.3% a year over the last three filed years against 1% over all 10, slowing (bottom 46% of its family); the newest year grew -5.9% (bottom 16%); research spending grew 12% a year (top 32%); capital spending grew -3% a year (bottom 49%) (its annual reports). Anika Therapeutics Inc. reported 2 product lines in fiscal 2025: OEM Channel at $64 million (57%), Commercial Channel at $48 million (43%); 1 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 36% of 88 in its family for expectations against reality.
From the record
Anika Therapeutics Inc.'s newest year against its own record: revenue of $113 million in fiscal 2025 came in 8.3% below the $123 million its prior three years' pace pointed to (bottom 39% of its family); net income of $11 million against a prior three-year average of $51 million (top 21%); a net margin of -9.6% against -42.8% before (top 26%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made